These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 27893333)

  • 1. Population-Level Survival for Patients With Chronic Myeloid Leukemia: Higher Survival in Sweden Than Internationally.
    Pulte D; Jansen L
    J Clin Oncol; 2017 Feb; 35(6):695-696. PubMed ID: 27893333
    [No Abstract]   [Full Text] [Related]  

  • 2. No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden.
    Gunnarsson N; Höglund M; Stenke L; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Wadenvik H; Richter J; Själander A
    Leukemia; 2017 Aug; 31(8):1825-1827. PubMed ID: 28461694
    [No Abstract]   [Full Text] [Related]  

  • 3. Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
    Gunnarsson N; Sandin F; Höglund M; Stenke L; Björkholm M; Lambe M; Olsson-Strömberg U; Richter J; Själander A
    Eur J Haematol; 2016 Oct; 97(4):387-92. PubMed ID: 26833713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia.
    Shivarov V; Grigorova D
    Br J Haematol; 2022 Jul; 198(2):e23-e25. PubMed ID: 35415917
    [No Abstract]   [Full Text] [Related]  

  • 5. Occurrence of chronic lymphocytic leukemia in patients with chronic myelogenous leukemia.
    Bhattacharyya PK
    Indian J Pathol Microbiol; 2013; 56(3):188-9. PubMed ID: 24152491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monitoring the chronic myeloid leukemia patients between 2008 and 2018; the experience of the Hematology and Bone Marrow Transplantation Unit Târgu-Mureș].
    Tunyogi AB; Lázár E; Benedek I; Sándor-Kéri J; Zsigmond A; Benedek I
    Orv Hetil; 2019 Jan; 160(2):67-72. PubMed ID: 30616371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the type of BCR/ABL junction predict the survival of patients with Ph1-positive chronic myeloid leukemia?
    Zaccaria A; Martinelli G; Testoni N; Zuffa E; Farabegoli P; Russo D; Guerrasio A; Tura S
    Leuk Lymphoma; 1995 Jan; 16(3-4):231-6. PubMed ID: 7719231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic myeloid leukemia].
    Matsuo T; Tomonaga M
    Nihon Rinsho; 2001 Nov; 59 Suppl 7():529-36. PubMed ID: 11808163
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic myeloid leukemia: a disease of youth in Brazil.
    de Campos MG; Arantes Ade M; de Oliveira JS; Chauffaille Mde L
    Leuk Res; 2010 Apr; 34(4):542-4. PubMed ID: 19796814
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.
    Mohammadi M; Cao Y; Glimelius I; Bottai M; Eloranta S; Smedby KE
    BMC Cancer; 2015 Nov; 15():850. PubMed ID: 26537111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study.
    Rebora P; Czene K; Antolini L; Gambacorti Passerini C; Reilly M; Valsecchi MG
    Am J Epidemiol; 2010 Nov; 172(9):1028-33. PubMed ID: 20861143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of comorbidities in chronic myeloid leukemia.
    Breccia M; Alimena G
    Leuk Res; 2013 Jul; 37(7):729-30. PubMed ID: 23628553
    [No Abstract]   [Full Text] [Related]  

  • 13. Conventional and novel tools for defining the risk of the individual patient with chronic myeloid leukemia and for monitoring treatment.
    Saglio G; Cilloni D
    Haematologica; 2004 Jan; 89(1):6-9. PubMed ID: 14754599
    [No Abstract]   [Full Text] [Related]  

  • 14. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W; Segel GB; Lichtman MA
    Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rising prevalence of chronic myeloid leukemia in France.
    Delord M; Foulon S; Cayuela JM; Rousselot P; Bonastre J
    Leuk Res; 2018 Jun; 69():94-99. PubMed ID: 29734071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
    Zhang JH; He YL; Zhu R; Du W; Xiao JH
    Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.
    Prejzner W
    Med Sci Monit; 2002 May; 8(5):BR193-7. PubMed ID: 12011769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment.
    Eskazan AE; Soysal T
    Leuk Lymphoma; 2015 May; 56(5):1554-5. PubMed ID: 25330444
    [No Abstract]   [Full Text] [Related]  

  • 20. Age at diagnosis of chronic myelogenous leukemia.
    Juneja SK; Januszewicz EH
    Blood; 1989 Oct; 74(5):1858-9. PubMed ID: 2790210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.